For PatientsPrescribing InformationProvider Login
why-upneeq-herowhy-upneeq-hero-mobile

Why Upneeq could be right for your adult patients

Upneeq is the first and only FDA-approved eye drop that’s been clinically proven to quickly and safely lift low-lying eyelids. It offers a non-surgical eyelid lift, in an easy-to-use once daily eye drop.

If your patient has low-lying eyelids (acquired ptosis), Upneeq can give them a more awake-looking appearance.

Get Your Patients Started Today
BEFORE
AFTER
After
Before

Actual patient. Individual results may vary. Average upper eyelid lift with Upneeq in clinical studies was 1 mm.

Upneeq is a first-in-class treatment with a mechanism of action that lifts upper eyelids

Directly activates α-adrenergic receptors in Müller’s muscle, stimulating contraction and elevation of the upper eyelids in adults with low-lying eyelids1

In vitro functional assays demonstrate that oxymetazoline has ≈5-fold greater affinity a receptors2,3 than for α1 receptors2,3

In vitro functional assays demonstrate that oxymetazoline has ≈5-fold greater affinity a receptors

Upneeq has a high completion rate in trials

97.5%

of subjects completed Upneeq clinical trials4

98%

of subjects were compliant with dosing Upneeq once daily4

2.2%

2.2% of patients in clinical trials discontinued treatment due to an adverse event4

Most common adverse reactions (incidence 1%-5%): punctate keratitis, conjunctival hyperemia, dry eye, blurred vision, instillation site pain, eye irritation and headache 1

Achieves significant
visual field improvement

Change from baseline in points seen in top 4 rows on LPFT (data from pooled analysis of 2 clinical trials)*4
Mean Change Chart
Upneeq (n=203)
Vehicle (n=101)
Error bars represent standard deviation of the mean change from baseline.
Why Upneeq Improvement
Upneeq demonstrated 3 times greater improvement in visual field compared to vehicle in clinical trials ( P<.01), as measured by LPFT (on Day 1 and Day 14 of treatment) 1
LPFT=Leicester Peripheral Field Test (measuring superior visual field).

*Two randomized, multicenter, double-masked, vehicle-controlled, Phase 3 studies compared once-daily Upneeq in 304 subjects with acquired blepharoptosis. Efficacy was assessed with the Leicester Peripheral Field Test (LPFT) and photographic measurement of Marginal Reflex Distance (MRD-1). There was a statistically significant difference in mean change in the LPFT from baseline after instillation of Upneeq and vehicle, with significantly greater increases in the study eye of the Upneeq group evident at the 2-hour point and maintained at the 6-hour time point. Greater MRD-1 increases were observed for the Upneeq group than the vehicle group on Day 1 at 6 hours post-dose and on Day 14 at 2 hours post-dose. 1

Introduce your patients to the eye drop that lifts.

Get Your Patients Started Today
References
1. Upneeq ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%. [Prescribing Information]. RVL Pharmaceuticals, Inc. 2024.
2. Hosten LO, Snyder C. Over-the-counter ocular decongestants in the United States - mechanisms of action and clinical utility for management of ocular redness. Clin Optom. 2020;12:95-105.
3. Haenisch B, Walstab J, Herberhold S, et al. Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010;24:729-739.
4. Slonim CB, Foster S, Jaros M, et al. Association of oxymetazoline hydrochloride, 0.1%, solution administration with visual field in acquired ptosis: a pooled analysis of 2 randomized clinical trials. JAMA Ophthalmol. 2020.

INDICATION

UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1% is indicated for the treatment of acquired blepharoptosis in adults.


IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS

  • Ptosis may be associated with neurologic or orbital diseases such as stroke and/or cerebral aneurysm, Horner syndrome, myasthenia gravis, external ophthalmoplegia, orbital infection and orbital masses. Consideration should be given to these conditions in the presence of ptosis with decreased levator muscle function and/or other neurologic signs.
  • Alpha-adrenergic agonists as a class may impact blood pressure. Advise UPNEEQ patients with cardiovascular disease, orthostatic hypotension, and/or uncontrolled hypertension or hypotension to seek medical care if their condition worsens.
  • Use UPNEEQ with caution in patients with cerebral or coronary insufficiency or Sjögren’s syndrome. Advise patients to seek medical care if signs and symptoms of potentiation of vascular insufficiency develop.
  • UPNEEQ may increase the risk of angle closure glaucoma in patients with untreated narrow-angle glaucoma. Advise patients to seek immediate medical care if signs and symptoms of acute narrow-angle glaucoma develop.
  • Patients should not touch the tip of the single patient-use container to their eye or to any surface, in order to avoid eye injury or contamination of the solution.

ADVERSE REACTIONS

Adverse reactions that occurred in 1-5% of subjects treated with UPNEEQ were punctate keratitis, conjunctival hyperemia, dry eye, blurred vision, instillation site pain, eye irritation and headache.


DRUG INTERACTIONS

  • Alpha-adrenergic agonists, as a class, may impact blood pressure. Caution in using drugs such as beta blockers, anti-hypertensives, and/or cardiac glycosides is advised. Caution should also be exercised in patients receiving alpha adrenergic receptor antagonists such as in the treatment of cardiovascular disease, or benign prostatic hypertrophy.
  • Caution is advised in patients taking monoamine oxidase inhibitors which can affect the metabolism and uptake of circulating amines.

To report SUSPECTED ADVERSE REACTIONS or product complaints, contact RVL Pharmaceuticals at 1-877-482-3788. You may also report SUSPECTED ADVERSE REACTIONS to the FDA by calling 1-800-FDA-1088 or visit www.fda.gov/medwatch.

INDICATION

UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1% is indicated for the treatment of acquired blepharoptosis in adults.


IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS

  • Ptosis may be associated with neurologic or orbital diseases such as stroke and/or cerebral aneurysm, Horner syndrome, myasthenia gravis, external ophthalmoplegia, orbital infection and orbital masses. Consideration should be given to these conditions in the presence of ptosis with decreased levator muscle function and/or other neurologic signs.
  • Alpha-adrenergic agonists as a class may impact blood pressure. Advise UPNEEQ patients with cardiovascular disease, orthostatic hypotension, and/or uncontrolled hypertension or hypotension to seek medical care if their condition worsens.
  • Use UPNEEQ with caution in patients with cerebral or coronary insufficiency or Sjögren’s syndrome. Advise patients to seek medical care if signs and symptoms of potentiation of vascular insufficiency develop.
  • UPNEEQ may increase the risk of angle closure glaucoma in patients with untreated narrow-angle glaucoma. Advise patients to seek immediate medical care if signs and symptoms of acute narrow-angle glaucoma develop.
  • Patients should not touch the tip of the single patient-use container to their eye or to any surface, in order to avoid eye injury or contamination of the solution.

ADVERSE REACTIONS

Adverse reactions that occurred in 1-5% of subjects treated with UPNEEQ were punctate keratitis, conjunctival hyperemia, dry eye, blurred vision, instillation site pain, eye irritation and headache.


DRUG INTERACTIONS

  • Alpha-adrenergic agonists, as a class, may impact blood pressure. Caution in using drugs such as beta blockers, anti-hypertensives, and/or cardiac glycosides is advised. Caution should also be exercised in patients receiving alpha adrenergic receptor antagonists such as in the treatment of cardiovascular disease, or benign prostatic hypertrophy.
  • Caution is advised in patients taking monoamine oxidase inhibitors which can affect the metabolism and uptake of circulating amines.

To report SUSPECTED ADVERSE REACTIONS or product complaints, contact RVL Pharmaceuticals at 1-877-482-3788. You may also report SUSPECTED ADVERSE REACTIONS to the FDA by calling 1-800-FDA-1088 or visit www.fda.gov/medwatch.

About UpneeqBefore and AfterWhat is Acquired PtosisResourcesContact Us
Prescribing Information
Privacy PolicyTerms of Use
FacebookTikTokInstagram

Distributed by: RVL Pharmaceuticals, Inc. Bridgewater, NJ 08807.©2025 RVL Pharmaceuticals, Inc. All rights reserved. PM-US-UPN-1741 03/25

Upneeq® is a registered trademark of RVL Pharmaceuticals, Inc.